Nirmatrelvir

7 trials 2 recruiting JAnti-infectives

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

2 Recruiting

4 Completed trials

7 Sponsors

12 Countries

Phase III

Phase II/III

Phase II

Phase IV

Phase I (Other)

Phase III: 2 Phase II/III: 1 Phase II: 2 Phase IV: 1 Phase I (Other): 1

Oversight events:

6 temporary halts across 2 trials

View oversight register →

Indications tested

Sponsors using this IMP

Pfizer Inc. 2 Amsterdam UMC Stichting 1 Atea Pharmaceuticals Inc. 1 Helse Bergen HF 1 Inserm 1 Region Vaesterbotten 1 Umea University 1

All trials

7 total

Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone … Pending

2025-522756-97-00 Phase II 1 country Region Vaesterbotten; Umea University
A Phase 2/3 Safety, Pharmacokinetics, and Efficacy Study ofNirmatrelvir/Ritonavir in Pediatric, Nonhospitalized Symptomatic Participants Wit… Recruiting

2023-509773-23-00 Phase II/III 2 countries Pfizer Inc.
OPtimisation of antiviral Therapy in Immunocompromised COVID-19 patients: a randomized factorial controlled strategy trial: the OPTICOV Stud… Recruiting

2022-501408-81-01 Phase II 3 countries Inserm
Antiviral treatment for long covid. Ended

2023-510337-29-00 Phase III 1 country Helse Bergen HF
TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents ag… Ended

2024-515263-60-00 Phase IV 1 country Stichting Amsterdam UMC
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who are Healthy Volunteers Co-administered the Medicine Ro… Ended

2023-503570-20-00 Phase I (Other) 1 country Pfizer Inc.
A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Ended

2023-504540-33-00 Phase III 6 countries Atea Pharmaceuticals Inc.

Showing 1–7 of 7 trials

← All drugs A–Z